Astrantus’s BioNTech BNTX Stock Holding History

Astrantus’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,000	Closed	-$516K	–	186
2021 Q4	$516K	Buy	+2,000	New	+$548K	0.39%	112

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Astrantus's BNTX Position: Q1 2022 in Review

Astrantus sold out of BioNTech (BNTX) in Q1 2022, closing a stake of 2,000 shares — an estimated $516K sold.

Astrantus first reported a position in BNTX in Q4 2021 and held it in 1 quarter. The position peaked at $516K in Q4 2021. 287 funds tracked by Wall St. Rank hold BNTX as of Q1 2022.

Astrantus reported no remaining BioNTech position as of Q1 2022 after selling out during the quarter.
Astrantus sold 2,000 BioNTech shares in Q1 2022, an estimated $516K.
Astrantus first reported a position in BioNTech in Q4 2021 and held it in 1 quarter.
Astrantus's BioNTech position peaked at $516K in Q4 2021.
287 funds tracked by Wall St. Rank held BioNTech as of Q1 2022.

Based on Astrantus's 13F filing for Q1 2022, filed 11 May 2022.